Results 41 to 50 of about 779,609 (165)

Current status of biosimilars in the treatment of inflammatory bowel diseases [PDF]

open access: yesIntestinal Research, 2016
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very
Dong Il Park
doaj   +1 more source

Letter: treatment with subcutaneous CT‐P13 in Crohn’s disease patients with intravenous infliximab failure [PDF]

open access: yesAlimentary Pharmacology & Therapeutics, 2022
LINKED CONTENTThis article is linked to Hanzel et al papers.
Caron, Bénédicte   +3 more
openaire   +3 more sources

Kontrollierte Einführung des Infliximab-Biosimilars CT-P13 bei Patienten mit Morbus Crohn und Colitis ulcerosa in einer großen deutschen Zentrumskohorte [PDF]

open access: yes, 2021
Einleitung: Das Infliximab Biosimilar CT-P13 wurde 2013 von der EMA im Rahmen eines Extrapolationsprozesses für die Behandlung von chronisch entzündlichen Darmerkrankungen (CED) ohne Zulassungsstudien genehmigt.
Röder, Helene
core   +1 more source

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease

open access: yesFrontiers in Pharmacology, 2021
Background: Crohn disease (CD) is a chronic inflammatory disease that affects quality of life. There are several drugs available for the treatment of CD, but their relative efficacy is unknown due to a lack of high-quality head-to-head randomized ...
Guozhi Wu   +11 more
doaj   +1 more source

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective [PDF]

open access: yesPLoS ONE
Nimer S. Alkhatib   +12 more
doaj   +2 more sources

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

open access: yes, 2017
Background: CT-P13 is a biosimilar of Remicade©, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD.
Guerra Veloz, María Fernanda   +8 more
core   +2 more sources

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2019
Patricia Shu Kurizky   +2 more
doaj   +2 more sources

The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease [PDF]

open access: yesJournal of Exploratory Research in Pharmacology, 2017
The advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost ...
Devika Kapuria, Rajiv Chhabra
openaire   +1 more source

Beyond Radical Emitters: Hot‐Exciton Electroluminescence From Singlet Diradicaloids

open access: yesAngewandte Chemie, EarlyView.
The first hot‐exciton mechanism in a singlet diradicaloid is demonstrated in a polychlorinated Thiele hydrocarbon‐based organic light‐emitting transistor. Reverse intersystem crossing involving the T2 and bright singly excited states enables electroluminescence beyond the 25% spin‐statistical limit, leading to remarkable external quantum efficiency ...
Mario Prosa   +12 more
wiley   +2 more sources

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. [PDF]

open access: yesDig Dis Sci, 2020
Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn's disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there are insufficient data from well-controlled trials to support non-medical ...
Bernard EJ, Fedorak RN, Jairath V.
europepmc   +4 more sources

Home - About - Disclaimer - Privacy